Brief: Endra Life Sciences Initiates Review Of Strategic Alternatives To Maximize Shareholder Value
25/03/2026 13:18
ENDRA Life Sciences Inc NDRA.O: ENDRA LIFE SCIENCES INITIATES REVIEW OF STRATEGIC ALTERNATIVES TO MAXIMIZE SHAREHOLDER VALUE ENDRA LIFE SCIENCES INC - BOARD TO EVALUATE STRATEGIC INVESTMENTS, MERGERS, ASSET SALES, OR SALE OF COMPANY ENDRA LIFE SCIENCES INC: CONTINUE TO EXECUTE ON ITS STRATEGIC AND OPERATING INITIATIVES DURING REVIEW PROCESS Source text: ID:nBw3JpQNsa Further company coverage: NDRA.O
Recent news on ENDRA Life Sciences
See all newsBrief: ENDRA Life Sciences - Enters First Amendment To Merger Agreement On October 1, 2026 - SEC Filing
ENDRA Life Sciences posts Q2 profit on digital asset gains ahead of merger
Endra Life Sciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Endra Life Sciences Inc Expected To Post A Loss Of 84 Cents A Share: Earnings Preview
Brief: ASP Isotopes Announces Proposed Merger Of Noble Africa With Endra Life Sciences